GlassScriptPhysician profile
Jonathan D Powell
NPI 1629011432
$11,162.38
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,079 · 2020: $4,000 · 2024: $83.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $83.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $83.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,261.44 | 2019 | |
| Shionogi INC | $4,000.00 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $500.00 | 2019 | |
| Astrazeneca Ab | $265.79 | 2019 | |
| Abbvie INC. | $83.19 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $51.96 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.